News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–2
Matches
2
Sources here
2
Companies here
1
Search results Stored financial headlines

Active search

2 matching headlines

Ticker or company: ALT1Main company stories
Clear
Latest

seekingalpha.com Earnings

Altimmune outlines PERFORMA Phase III MASH 52-week data readout expected in 2029 while advancing AUD Phase III planning

Earnings Call Insights: Altimmune (ALT) Q2 2026 MANAGEMENT VIEW * "2026 is proving to be a year of significant progress as Altimmune evolves into a late-stage company dedicated to serious liver diseases," said Chairman, CEO & President Jerome Durso, adding, "Last week we announced the initiation of the PERFORMA Phase III trial as we began enrolling patients in …

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will …

ALT1 main company
Sharemaestro market context Price below Trend Line 52 weeks -27.6% · Next-week setup negative 17.4% ALT1 stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

No headlines match this search

Try fewer filters or a broader date range.

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context